Investigator's Brochure (IB) Table
Drugs
| Drug Name Sort descending | Drug Company | IB Date | Risk List Available? |
|---|---|---|---|
| ABT-267, ABT 333, ABT-450 and Ritonavir | AbbVie | June 2017 | |
| Bedaquiline (TMC207) | Janssen Research & Development | February 2019 | |
| Cemiplimab (REGN2810) - New | Regeneron Pharmaceuticals, Inc. | May 2019 | |
| Dapivirine (Microbicide Gel) | International Partnership for Microbicides | May 2017 | |
| Dapivirine (Vaginal Ring) | International Partnership For Microbicides | July 2018 | |
| Delamanid (OPC-67683) | Otsuka | April 2019 | |
| Dolutegravir (GSK1349572) | ViiV Healthcare | November 2018 | |
| Doravirine (MK-1439) - New | Merck | May 2019 | |
| Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) - New | Merck | May 2019 | |
| Emtricitabine/Tenofovir Disoproxil Fumarate (Truvada) | Gilead Sciences | December 2016 | YES |
| Etravirine (TMC125, Intelence) | Janssen Research & Development | April 2018 | |
| Glecaprevir (ABT-493) and Pibrentasvir (ABT-530) - New | AbbVie | December 2018 | |
| GSK1265744 (Cabotegravir) | ViiV Healthcare | December 2018 | |
| HEC Placebo Gel | CONRAD | September 2011 | |
| Maraviroc (UK-427857) | ViiV Healthcare | October 2017 | |
| PC-1005 | Population Council | April 2017 | |
| Raltegravir (Isentress) | Merck | September 2017 | YES |
| Rifapentine | Sanofi | August 2013 | |
| Rilpivirine (TMC278, Edurant) - New | Janssen Research & Development | July 2019 | |
| Sofosbuvir/Velapatasvir (Epclusa) | Gilead | July 2016 |
Vaccines
| Vaccine Name Sort descending | Vaccine Company | IB Date | Risk List Available? |
|---|---|---|---|
| 10-1074 | Rockerfeller University/Mass Biologics | October 2018 | |
| Ad26.ENVA.01 | Crucell Holland BV | June 2013 | |
| AIDSVAX B/E | Global Solutions for Infectious Diseases | March 2016 | |
| ALVAC-HIV (vCP2438) | Sanofi Pasteur | August 2017 | |
| B63521^11 gp120 - New | DAIDS/NIAID/NIH | July 2019 | |
| BG505 SOSIP.664 gp140 - New | DAIDS/NIAID/NIH | August 2019 | |
| Bivalent Subtype C gp120 with Aluminum Hydroxide Adjuvant | NIAID/NIH | June 2015 | |
| Bivalent Subtype C gp120/AS01B | GlaxoSmithKline | July 2016 | |
| Bivalent Subtype C gp120/MF59 | GlaxoSmithKline | July 2016 | |
| CH505TF gp120 Transient | DAIDS/NIAID/NIH | December 2018 | |
| DNA CON-S env | DAIDS/NIAID/NIH | June 2017 | |
| DNA Mosaic-Tre env DNA Vaccine | DAIDS/NIAID/NIH | July 2016 | |
| DNA-HIV-PT123 | IPPOX | January 2019 | |
| DNA-HIV-PT123/NYVAC-HIV-PT1/NYVAC-HIV-PT4 vaccine | IPPOX/EuroVacc | August 2013 | |
| EnvSeq-1 Vaccine (CH505TF gp120) | DAIDS/NIAID/NIH | August 2019 | |
| GEO-D02 and MVA-HIV62B Vaccine - New | GeoVax | June 2019 | |
| GEO-D03 and MVA-HIV62B Vaccines (Preventative) | GeoVax | June 2013 | |
| GLA-SE | Infectious Disease Research Institute (IDRI) | April 2019 | |
| HIV-1 Multiantigen pDNA Vaccine and Human IL-12 pDNA | Profectus BioSciences | August 2018 | |
| IHV01 - New | Profectus BioSciences Inc. | March 2019 |